$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

$mdgl Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000162828024044445 Filed on October 31, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$62.18M
YoY Change
Cost Of Revenue		$2.152M
YoY Change
Gross Profit		$60.02M
YoY Change
Gross Profit Margin		96.54%
Selling, General & Admin		$107.6M
YoY Change		289.8%
% of Gross Profit		179.24%
Research & Development		$68.74M
YoY Change		-3.11%
% of Gross Profit		114.53%
Depreciation & Amortization		$298.0K
YoY Change		112.86%
% of Gross Profit		0.5%
Operating Expenses		$178.5M
YoY Change		81.13%
Operating Profit		-$116.3M
YoY Change		18.03%
Interest Expense		$3.679M
YoY Change		4.99%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income		-$107.0M
YoY Change		8.37%
Income Tax
% Of Pretax Income
Net Earnings		-$107.0M
YoY Change		8.33%
Net Earnings / Revenue		-172.04%
Basic Earnings Per Share		-$4.92
Diluted Earnings Per Share		-$4.92
COMMON SHARES
Basic Shares Outstanding	21.81M shares	21.71M shares
Diluted Shares Outstanding		21.75M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$998.6M
YoY Change		329.79%
Cash & Equivalents		$232.7M
Short-Term Investments		$765.9M
Other Short-Term Assets
YoY Change
Inventory		$8.715M
Prepaid Expenses
Receivables		$30.46M
Other Receivables
Total Short-Term Assets		$1.064B
YoY Change		351.72%
LONG-TERM ASSETS
Property, Plant & Equipment		$2.268M
YoY Change		244.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$9.599M
YoY Change		284.73%
TOTAL ASSETS
Total Short-Term Assets		$1.064B
Total Long-Term Assets		$9.599M
Total Assets		$1.073B
YoY Change		351.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$45.97M
YoY Change		177.87%
Accrued Expenses		$131.0M
YoY Change		58.58%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$177.8M
YoY Change		78.44%
LONG-TERM LIABILITIES
Long-Term Debt		$117.1M
YoY Change		2.06%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$118.3M
YoY Change		1.91%
TOTAL LIABILITIES
Total Short-Term Liabilities		$177.8M
Total Long-Term Liabilities		$118.3M
Total Liabilities		$296.1M
YoY Change		37.27%
SHAREHOLDERS EQUITY
Retained Earnings		-$1.743B
YoY Change		42.37%
Common Stock		$2.519B
YoY Change		102.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$777.2M
YoY Change
Total Liabilities & Shareholders Equity		$1.073B
YoY Change		351.02%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$107.0M
YoY Change		8.33%
Depreciation, Depletion And Amortization		$298.0K
YoY Change		112.86%
Cash From Operating Activities		-$66.98M
YoY Change		-21.12%
INVESTING ACTIVITIES
Capital Expenditures		$779.0K
YoY Change		129.12%
Acquisitions
YoY Change
Other Investing Activities		-$201.6M
YoY Change		-498.92%
Cash From Investing Activities		-$202.4M
YoY Change		-503.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		7.462M
YoY Change		-61.89%
NET CHANGE
Cash From Operating Activities		-66.98M
Cash From Investing Activities		-202.4M
Cash From Financing Activities		7.462M
Net Change In Cash		-261.9M
YoY Change		1629.94%
FREE CASH FLOW
Cash From Operating Activities		-$66.98M
Capital Expenditures		$779.0K
Free Cash Flow		-$67.76M
YoY Change		-20.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-196000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-151971000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	857120000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity Central Index Key EntityCentralIndexKey	0001157601
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-33277
	dei	Entity Registrant Name EntityRegistrantName	MADRIGAL PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3508648
	dei	Entity Address Address Line1 EntityAddressAddressLine1	Four Tower Bridge
	dei	Entity Address Address Line2 EntityAddressAddressLine2	200 Barr Harbor Drive, Suite 200
	dei	Entity Address City Or Town EntityAddressCityOrTown	West Conshohocken
	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19428
	dei	City Area Code CityAreaCode	267
	dei	Local Phone Number LocalPhoneNumber	824-2827
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21810407	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	232684000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99915000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	765943000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	534216000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	30463000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20861000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3150000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	1063666000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	637281000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2268000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1553000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4819000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1713000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	527000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	177847000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	118548000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	117087000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	115480000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1176000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1186000	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	118263000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	116666000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	296110000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2369797	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2369797	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2518648000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1741153000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1271000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	468000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1742766000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1336290000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	777155000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	405333000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1073265000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	640547000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	62175000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	76813000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2024Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2152000	usd
CY2023Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	0	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2788000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	0	usd
CY2024Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	68742000	usd
CY2023Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	70951000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	211070000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	201710000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	107585000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27583000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	293834000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61610000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	178479000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	98534000	usd
	us-gaap	Operating Expenses OperatingExpenses	507692000	usd
	us-gaap	Operating Expenses OperatingExpenses	263320000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-116304000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-98534000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-430879000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3298000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	35575000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	10625000	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	3679000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	3504000	usd
	us-gaap	Interest Expense InterestExpense	11172000	usd
	us-gaap	Interest Expense InterestExpense	8741000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-106964000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-98740000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-406476000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-261436000	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.92
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.92
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.34
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.27
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-14.27
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21745929	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21745929	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21052544	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21052544	shares
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-106964000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1639000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	47000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	803000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-10000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-105325000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-98693000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-405673000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-261446000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	405333000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	311560000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	19902000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-640000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-147541000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	850759000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	85950000	usd
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 Par Value Per Share
	dei	Trading Symbol TradingSymbol	MDGL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q3	us-gaap	Restricted Cash RestrictedCash	5000000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	8715000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2512000	usd
CY2024Q3	us-gaap	Assets Assets	1073265000	usd
CY2023Q4	us-gaap	Assets Assets	640547000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	45966000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	28041000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	131003000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89980000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	878000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	235214000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2369797	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2369797	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21806436	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21806436	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19875427	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19875427	shares
	us-gaap	Operating Income Loss OperatingIncomeLoss	-263320000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	13019000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-19.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-19.31
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18476414	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18476414	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18326154	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18326154	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-98740000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-406476000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-261436000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	24404000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	17898000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1639000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-106964000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	777155000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	197389000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	11250000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-54000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	544000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-76896000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	150136000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21754000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	10973000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	195000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-85800000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	103506000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2731000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	195000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-85800000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	103506000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2731000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	12660000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	47000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	121000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-98740000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	22249000	usd
	us-gaap	Profit Loss ProfitLoss	-406476000	usd
	us-gaap	Profit Loss ProfitLoss	-261436000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	62204000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	34883000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	733000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	385000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1607000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1661000	usd
	mdgl	Operating Lease Right Of Use Asset Periodic Reduction Increase OperatingLeaseRightOfUseAssetPeriodicReductionIncrease	-458000	usd
	mdgl	Operating Lease Right Of Use Asset Periodic Reduction Increase OperatingLeaseRightOfUseAssetPeriodicReductionIncrease	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	30463000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	17711000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	523000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8715000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	17925000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-7289000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	41023000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8851000	usd
	mdgl	Increase Decrease In Accrued Interest Net Of Interest Received IncreaseDecreaseInAccruedInterestNetOfInterestReceived	-10755000	usd
	mdgl	Increase Decrease In Accrued Interest Net Of Interest Received IncreaseDecreaseInAccruedInterestNetOfInterestReceived	-3127000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-351086000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-244297000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	781021000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	359549000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	560852000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	219595000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5000000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1267000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	443000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-226436000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-140397000	usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	0	usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	65000000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	363000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	715291000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	115200000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	137769000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-269494000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99915000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	331549000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	237684000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	12660000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	47000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	121000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-98740000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	22249000	usd
	us-gaap	Profit Loss ProfitLoss	-406476000	usd
	us-gaap	Profit Loss ProfitLoss	-261436000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	62204000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	34883000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	733000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	385000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1607000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1661000	usd
	mdgl	Operating Lease Right Of Use Asset Periodic Reduction Increase OperatingLeaseRightOfUseAssetPeriodicReductionIncrease	-458000	usd
	mdgl	Operating Lease Right Of Use Asset Periodic Reduction Increase OperatingLeaseRightOfUseAssetPeriodicReductionIncrease	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	30463000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	17711000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	523000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8715000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	17925000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-7289000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	41023000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8851000	usd
	mdgl	Increase Decrease In Accrued Interest Net Of Interest Received IncreaseDecreaseInAccruedInterestNetOfInterestReceived	-10755000	usd
	mdgl	Increase Decrease In Accrued Interest Net Of Interest Received IncreaseDecreaseInAccruedInterestNetOfInterestReceived	-3127000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-351086000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-244297000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	781021000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	560852000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	219595000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5000000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1267000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	443000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-226436000	usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	0	usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	65000000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	363000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	715291000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	115200000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	137769000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-269494000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99915000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	331549000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62055000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1168000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1628000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62055000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1168000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1628000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Use of Estimates </span></div>The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Concentrations of Credit Risk and Significant Customers</span></div>The Company generates revenue from a small number of large, reputable customers.
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Use of Estimates </span></div>The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Concentrations of Credit Risk and Significant Customers</span></div>The Company generates revenue from a small number of large, reputable customers.
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	mdgl	Deferred Tax Assets Percentage Of Valuation Allowance DeferredTaxAssetsPercentageOfValuationAllowance	1
	us-gaap	Net Income Loss NetIncomeLoss	-406500000	usd
	mdgl	Deferred Tax Assets Percentage Of Valuation Allowance DeferredTaxAssetsPercentageOfValuationAllowance	1
	us-gaap	Net Income Loss NetIncomeLoss	-406500000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1742800000	usd
CY2024Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	574000000	usd
CY2024Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	85900000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	5000000.0	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	237684000	usd
CY2024Q3	mdgl	Cash Cash Equivalents And Short Term Investments At Cost CashCashEquivalentsAndShortTermInvestmentsAtCost	1002356000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1304000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	99915000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	99915000	usd
CY2023Q4	mdgl	Cash Cash Equivalents And Short Term Investments At Cost CashCashEquivalentsAndShortTermInvestmentsAtCost	633663000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	476000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	634131000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	usd
CY2024Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5389000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3326000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	8715000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1742800000	usd
CY2024Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	85900000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	5000000.0	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	237684000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	237684000	usd
CY2024Q3	mdgl	Cash Cash Equivalents And Short Term Investments At Cost CashCashEquivalentsAndShortTermInvestmentsAtCost	1002356000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1304000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	33000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1003627000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	99915000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	99915000	usd
CY2023Q4	mdgl	Cash Cash Equivalents And Short Term Investments At Cost CashCashEquivalentsAndShortTermInvestmentsAtCost	633663000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	476000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	634131000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	usd
CY2024Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5389000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3326000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2024Q3	mdgl	Accrued Contract Research Costs Current AccruedContractResearchCostsCurrent	59809000	usd
CY2024Q3	mdgl	Accrued Other Clinical Study Related Costs Current AccruedOtherClinicalStudyRelatedCostsCurrent	1496000	usd
CY2023Q4	mdgl	Accrued Other Clinical Study Related Costs Current AccruedOtherClinicalStudyRelatedCostsCurrent	3724000	usd
CY2024Q3	mdgl	Accrued Manufacturing And Drug Supply Current AccruedManufacturingAndDrugSupplyCurrent	2291000	usd
CY2023Q4	mdgl	Accrued Manufacturing And Drug Supply Current AccruedManufacturingAndDrugSupplyCurrent	9705000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	29684000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17030000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	23095000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6814000	usd
CY2024Q3	mdgl	Accrued Liabilities Gross AccruedLiabilitiesGross	7816000	usd
CY2023Q4	mdgl	Accrued Liabilities Gross AccruedLiabilitiesGross	0	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6812000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1970000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	131003000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89980000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	14899	shares
CY2022Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	600000	usd
CY2023Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	900000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	3067000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	12184000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	79197000	usd
CY2024Q3	mdgl	Long Term Debt Maturity After Year Two LongTermDebtMaturityAfterYearTwo	53247000	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	147695000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	26542000	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	4066000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	117087000	usd
	mdgl	Common Stock Voting Rights Number CommonStockVotingRightsNumber	1	vote
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2355779	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	79.94
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	162517	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	234.84
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	748143	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	76.35
CY2024Q3	mdgl	Accrued Contract Research Costs Current AccruedContractResearchCostsCurrent	59809000	usd
CY2023Q4	mdgl	Accrued Contract Research Costs Current AccruedContractResearchCostsCurrent	50737000	usd
CY2024Q3	mdgl	Accrued Other Clinical Study Related Costs Current AccruedOtherClinicalStudyRelatedCostsCurrent	1496000	usd
CY2023Q4	mdgl	Accrued Other Clinical Study Related Costs Current AccruedOtherClinicalStudyRelatedCostsCurrent	3724000	usd
CY2024Q3	mdgl	Accrued Manufacturing And Drug Supply Current AccruedManufacturingAndDrugSupplyCurrent	2291000	usd
CY2023Q4	mdgl	Accrued Manufacturing And Drug Supply Current AccruedManufacturingAndDrugSupplyCurrent	9705000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	29684000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	23095000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6814000	usd
CY2024Q3	mdgl	Accrued Liabilities Gross AccruedLiabilitiesGross	7816000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6812000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1970000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	131003000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89980000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	14899	shares
CY2022Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	600000	usd
CY2023Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	900000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	3067000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	12184000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	79197000	usd
CY2024Q3	mdgl	Long Term Debt Maturity After Year Two LongTermDebtMaturityAfterYearTwo	53247000	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	147695000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	26542000	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	4066000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	117087000	usd
	mdgl	Common Stock Voting Rights Number CommonStockVotingRightsNumber	1	vote
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2355779	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	79.94
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	162517	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	234.84
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	748143	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	76.35
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	68535	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	121.89
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	68535	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	121.89
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1701618	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	94.62
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1297563	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	78.45
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17898000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12660000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62204000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34883000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17898000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12660000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62204000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34883000	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	139100000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M15D
	us-gaap	Revenues Revenues	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1600000	usd
CY2024Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1200000	usd
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1701618	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	94.62
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1297563	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	78.45
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17898000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12660000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62204000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34883000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17898000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12660000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62204000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34883000	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	139100000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M15D
	us-gaap	Revenues Revenues	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1600000	usd
CY2024Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1200000	usd
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-044445-index-headers.html	Edgar Link	pending
0001628280-24-044445-index.html	Edgar Link	pending
0001628280-24-044445.txt	Edgar Link	pending
0001628280-24-044445-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
formxex102herculesamendm.htm	Edgar Link	pending
formxex102herculesamendm001.jpg	Edgar Link	pending
formxex102herculesamendm002.jpg	Edgar Link	pending
formxex102herculesamendm003.jpg	Edgar Link	pending
formxex102herculesamendm004.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
formxex102herculesamendm005.jpg	Edgar Link	pending
formxex102herculesamendm006.jpg	Edgar Link	pending
formxex102herculesamendm007.jpg	Edgar Link	pending
formxex102herculesamendm008.jpg	Edgar Link	pending
formxex102herculesamendm009.jpg	Edgar Link	pending
formxex102herculesamendm010.jpg	Edgar Link	pending
formxex102herculesamendm011.jpg	Edgar Link	pending
formxex102herculesamendm012.jpg	Edgar Link	pending
formxex102herculesamendm013.jpg	Edgar Link	pending
formxex102herculesamendm014.jpg	Edgar Link	pending
formxex102herculesamendm015.jpg	Edgar Link	pending
formxex102herculesamendm016.jpg	Edgar Link	pending
formxex102herculesamendm017.jpg	Edgar Link	pending
formxex102herculesamendm018.jpg	Edgar Link	pending
formxex102herculesamendm019.jpg	Edgar Link	pending
formxex102herculesamendm020.jpg	Edgar Link	pending
formxex102herculesamendm021.jpg	Edgar Link	pending
formxex102herculesamendm022.jpg	Edgar Link	pending
formxex102herculesamendm023.jpg	Edgar Link	pending
formxex102herculesamendm024.jpg	Edgar Link	pending
formxex102herculesamendm025.jpg	Edgar Link	pending
formxex102herculesamendm026.jpg	Edgar Link	pending
formxex102herculesamendm027.jpg	Edgar Link	pending
formxex102herculesamendm028.jpg	Edgar Link	pending
formxex102herculesamendm029.jpg	Edgar Link	pending
formxex102herculesamendm030.jpg	Edgar Link	pending
formxex102herculesamendm031.jpg	Edgar Link	pending
mdgl-20240930.htm	Edgar Link	pending
mdgl-20240930.xsd	Edgar Link	pending
mdgl-20240930xex101.htm	Edgar Link	pending
mdgl-20240930xex311.htm	Edgar Link	pending
mdgl-20240930xex312.htm	Edgar Link	pending
mdgl-20240930xex321.htm	Edgar Link	pending
mdgl-20240930_cal.xml	Edgar Link	unprocessable
mdgl-20240930_def.xml	Edgar Link	unprocessable
mdgllogo.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
mdgl-20240930_pre.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mdgl-20240930_htm.xml	Edgar Link	completed
mdgl-20240930_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

2024 Q4 Form 10-Q Financial Statement

#000162828024044445 Filed on October 31, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

2024 Q4 Form 10-Q Financial Statement

#000162828024044445 Filed on October 31, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl